Safety and Genital Effects of Toremifene Compared With Tamoxifen
For women diagnosed with breast cancer (BC), endocrine options for treatment depend on menopausal status. In premenopausal women, choice of adjuvant endocrine therapy is often based on the patient’s risk of recurrence and involves the use of ovarian suppression plus endocrine therapy. Selective estrogen receptor modulators are the mainstay of adjuvant BC therapy in this population. Read more |
Adjuvant Paclitaxel and Carboplatin in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of BC cases in the U.S. However, despite its lower prevalence, this disease has a more virulent and aggressive course. Adding to this burden, approximately 11% of TNBC patients manifest BRAC1/2 variants, resulting in a dysfunctional BRCA pathway. These variants are associated with abnormal DNA repair and genome-wide instability. Read more. |